BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 13 2025
0mins
Should l Buy SNY?
Source: Globenewswire
Investigation Announcements: Brodsky & Smith is reminding investors about ongoing investigations into several companies, including Crown Electrokinetics, Elevation Oncology, Sitio Royalties, and Vigil Neuroscience, regarding potential breaches of fiduciary duties by their boards during acquisition processes.
Acquisition Details: Each company mentioned is in the process of being acquired at specific cash prices per share, with concerns raised about whether these offers provide fair value to shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 47.530
Low
57.00
Averages
79.36
High
119.07
Current: 47.530
Low
57.00
Averages
79.36
High
119.07
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Shareholders Await Recovery Amid Dividend Payouts
- Medical Device Market Performance: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a 35% drop in stock price over the past five years; its 3.3% dividend yield provides stable returns, alleviating shareholder concerns amid price volatility.
- Pharmaceutical Sales Challenges: Sanofi's Dupixent saw a 32.2% sales increase to €4.2 billion in 2025, yet faces patent expiration risks; the company anticipates a high-single-digit percentage sales growth in 2026, supported by a 5% dividend yield that offers ongoing shareholder returns.
- Growth Portfolio Potential: Bristol Myers Squibb's growth portfolio revenue rose from $22.6 billion to $26.4 billion in 2025, despite a 10% stock price decline over five years; its 4.2% dividend yield remains attractive to investors, particularly as legacy portfolio revenues decline.
- Market Outlook Uncertainty: Despite overall poor performance in healthcare stocks, investors remain optimistic about dividends from Medtronic, Sanofi, and Bristol Myers Squibb, as these companies enhance shareholder confidence through consistent dividend payments, reflecting the long-term investment value in the healthcare sector.
See More
Healthcare Investors Hold Steady Amid Stock Declines
- Medtronic Financials: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a more than 35% stock price drop over the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating a strong commitment to shareholders.
- Sanofi Drug Sales: Sanofi's Dupixent saw a 32.2% sales increase in 2025, generating €4.2 billion, and while facing patent expiration risks, total sales are expected to grow in the high single digits in 2026, with a dividend yield of 4.69%, providing stable returns for shareholders.
- Bristol Myers Growth Potential: Bristol Myers' growth portfolio revenue increased from $22.6 billion in 2024 to $26.4 billion in 2025, and although overall revenue is expected to slightly decline in 2026, the company maintains a 4.2% dividend yield, showcasing resilience and potential in the market.
- Investor Confidence: Despite challenges in healthcare stocks, all three companies offer attractive dividend yields, encouraging investors to hold their positions in a volatile market, reflecting the long-term investment value of the healthcare sector.
See More
Three Healthcare Stocks Offering Dividends Amidst Recovery Wait
- Medtronic's Financial Status: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a stock price decline of over 35% in the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating its commitment to shareholders.
- Sanofi's Challenges: Sanofi's Dupixent drug saw a 32.2% sales increase in 2025, generating €4.2 billion, but faces patent expiration risks; the company expects total sales to rise by a high-single-digit percentage in 2026 while offering a 5% dividend yield to attract investors.
- Bristol Myers Squibb's Growth Potential: Although Bristol Myers Squibb's stock price has dropped about 10% over the past five years, its
See More
EMA Endorses Five New Medicines Including Sanofi's Autoimmune Drug
- New Drug Endorsements: The EMA expert panel endorsed five new medicines this week, including Sanofi's (SNY) autoimmune drug Cenrifki, which targets multiple sclerosis and is expected to significantly improve patient quality of life.
- Sanofi's Drug Progress: Cenrifki received a positive opinion from the CHMP for patients with secondary progressive multiple sclerosis who have not relapsed in the past two years, with final approval anticipated in the coming months.
- Arrowhead's Approval: Arrowhead Pharmaceuticals (ARWR) received a positive opinion for its RNA medicine Redemplo (plozasiran), aimed at reducing triglycerides in adults with familial chylomicronemia syndrome, with a final decision expected in Q2 2026.
- Novartis Gene Therapy: Novartis (NVS) announced that its gene therapy Itvisma received CHMP recommendation for patients aged two and older with spinal muscular atrophy, with final authorization expected in roughly two months, further enhancing the company's position in the rare disease market.
See More
Sanofi Reports Strong Q1 Results Exceeding Expectations
- Significant Earnings Growth: Sanofi reported Q1 earnings per share of €1.88 ($2.20), reflecting a 5.0% increase at actual exchange rates, surpassing the consensus estimate of €1.80, indicating strong market performance.
- Sales Surge: The company achieved sales of €10.51 billion, a 13.6% increase at constant exchange rates, driven by robust demand for core products, particularly Dupixent, which saw a 30.8% rise to €4.2 billion, further solidifying its market position.
- Vaccine Sales Increase: Vaccine sales rose by 2.1% to €1.3 billion, benefiting from contributions from Heplisav-B, showcasing the company's ongoing potential in the vaccine sector.
- Optimistic Future Outlook: Sanofi reaffirmed its full-year sales growth forecast of high single digits, with business EPS expected to grow slightly faster than sales, and analysts believe the incoming CEO, Belén Garijo, will bring opportunities for strategic transformation.
See More
Sanofi Reports Strong Q1 Results Driven by Dupixent Sales
- Revenue Growth: Sanofi reported first-quarter sales of €10.51 billion, exceeding analyst expectations of €10.22 billion, indicating strong market performance that is likely to boost investor confidence.
- Operating Income Increase: The company’s operating income for the first quarter reached €2.97 billion, surpassing the forecast of €2.85 billion, reflecting robust growth in its core business that may enhance future shareholder returns.
- Strong Dupixent Sales: Sales of Dupixent surged 30.8% year-over-year to €4.17 billion, comfortably beating analysts' forecast of €3.89 billion, demonstrating sustained strong demand for the drug in asthma and eczema treatment.
- Vaccine Division Performance: The vaccines division generated sales of €1.3 billion, with solid demand for polio and pertussis vaccines offsetting weaker sales of flu and RSV shots, indicating stability in the company's vaccine market.
See More
Healthcare Shareholders Await Recovery Amid Dividend Payouts
- Medical Device Market Performance: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a 35% drop in stock price over the past five years; its 3.3% dividend yield provides stable returns, alleviating shareholder concerns amid price volatility.
- Pharmaceutical Sales Challenges: Sanofi's Dupixent saw a 32.2% sales increase to €4.2 billion in 2025, yet faces patent expiration risks; the company anticipates a high-single-digit percentage sales growth in 2026, supported by a 5% dividend yield that offers ongoing shareholder returns.
- Growth Portfolio Potential: Bristol Myers Squibb's growth portfolio revenue rose from $22.6 billion to $26.4 billion in 2025, despite a 10% stock price decline over five years; its 4.2% dividend yield remains attractive to investors, particularly as legacy portfolio revenues decline.
- Market Outlook Uncertainty: Despite overall poor performance in healthcare stocks, investors remain optimistic about dividends from Medtronic, Sanofi, and Bristol Myers Squibb, as these companies enhance shareholder confidence through consistent dividend payments, reflecting the long-term investment value in the healthcare sector.
See More
Healthcare Investors Hold Steady Amid Stock Declines
- Medtronic Financials: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a more than 35% stock price drop over the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating a strong commitment to shareholders.
- Sanofi Drug Sales: Sanofi's Dupixent saw a 32.2% sales increase in 2025, generating €4.2 billion, and while facing patent expiration risks, total sales are expected to grow in the high single digits in 2026, with a dividend yield of 4.69%, providing stable returns for shareholders.
- Bristol Myers Growth Potential: Bristol Myers' growth portfolio revenue increased from $22.6 billion in 2024 to $26.4 billion in 2025, and although overall revenue is expected to slightly decline in 2026, the company maintains a 4.2% dividend yield, showcasing resilience and potential in the market.
- Investor Confidence: Despite challenges in healthcare stocks, all three companies offer attractive dividend yields, encouraging investors to hold their positions in a volatile market, reflecting the long-term investment value of the healthcare sector.
See More
Three Healthcare Stocks Offering Dividends Amidst Recovery Wait
- Medtronic's Financial Status: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a stock price decline of over 35% in the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating its commitment to shareholders.
- Sanofi's Challenges: Sanofi's Dupixent drug saw a 32.2% sales increase in 2025, generating €4.2 billion, but faces patent expiration risks; the company expects total sales to rise by a high-single-digit percentage in 2026 while offering a 5% dividend yield to attract investors.
- Bristol Myers Squibb's Growth Potential: Although Bristol Myers Squibb's stock price has dropped about 10% over the past five years, its
See More
EMA Endorses Five New Medicines Including Sanofi's Autoimmune Drug
- New Drug Endorsements: The EMA expert panel endorsed five new medicines this week, including Sanofi's (SNY) autoimmune drug Cenrifki, which targets multiple sclerosis and is expected to significantly improve patient quality of life.
- Sanofi's Drug Progress: Cenrifki received a positive opinion from the CHMP for patients with secondary progressive multiple sclerosis who have not relapsed in the past two years, with final approval anticipated in the coming months.
- Arrowhead's Approval: Arrowhead Pharmaceuticals (ARWR) received a positive opinion for its RNA medicine Redemplo (plozasiran), aimed at reducing triglycerides in adults with familial chylomicronemia syndrome, with a final decision expected in Q2 2026.
- Novartis Gene Therapy: Novartis (NVS) announced that its gene therapy Itvisma received CHMP recommendation for patients aged two and older with spinal muscular atrophy, with final authorization expected in roughly two months, further enhancing the company's position in the rare disease market.
See More
Sanofi Reports Strong Q1 Results Exceeding Expectations
- Significant Earnings Growth: Sanofi reported Q1 earnings per share of €1.88 ($2.20), reflecting a 5.0% increase at actual exchange rates, surpassing the consensus estimate of €1.80, indicating strong market performance.
- Sales Surge: The company achieved sales of €10.51 billion, a 13.6% increase at constant exchange rates, driven by robust demand for core products, particularly Dupixent, which saw a 30.8% rise to €4.2 billion, further solidifying its market position.
- Vaccine Sales Increase: Vaccine sales rose by 2.1% to €1.3 billion, benefiting from contributions from Heplisav-B, showcasing the company's ongoing potential in the vaccine sector.
- Optimistic Future Outlook: Sanofi reaffirmed its full-year sales growth forecast of high single digits, with business EPS expected to grow slightly faster than sales, and analysts believe the incoming CEO, Belén Garijo, will bring opportunities for strategic transformation.
See More
Sanofi Reports Strong Q1 Results Driven by Dupixent Sales
- Revenue Growth: Sanofi reported first-quarter sales of €10.51 billion, exceeding analyst expectations of €10.22 billion, indicating strong market performance that is likely to boost investor confidence.
- Operating Income Increase: The company’s operating income for the first quarter reached €2.97 billion, surpassing the forecast of €2.85 billion, reflecting robust growth in its core business that may enhance future shareholder returns.
- Strong Dupixent Sales: Sales of Dupixent surged 30.8% year-over-year to €4.17 billion, comfortably beating analysts' forecast of €3.89 billion, demonstrating sustained strong demand for the drug in asthma and eczema treatment.
- Vaccine Division Performance: The vaccines division generated sales of €1.3 billion, with solid demand for polio and pertussis vaccines offsetting weaker sales of flu and RSV shots, indicating stability in the company's vaccine market.
See More
